Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26128975 | 1.00 | MEN1 (0.33) | MEN1KMT2AHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL26128972 | 1.00 | MEN1 (0.33) | MEN1KMT2AHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL9679186 | 0.82 | MEN1 (0.39) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL7430144 | 0.81 | MEN1 (0.35) | MEN1KMT2AHTT | |
| SCHEMBL8973374 | 0.80 | MEN1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL8973716 | 0.80 | MEN1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL8741513 | 0.80 | MEN1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL10431159 | 0.80 | MEN1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL13460299 | 0.80 | MEN1 (0.36) | MEN1KMT2AHTTL3MBTL1 | |
| SCHEMBL9724464 | 0.79 | MEN1 (0.36) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3110810-A1 | PYRAZOLE AMIDE DERIVATIVE | Teijin Pharma Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| EP-2428507-B1 | Cannabinoid receptor ligands | ABBVIE BAHAMAS LTD (BS) | 2015-10-21 | — | — | EP | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| EP-2896615-A1 | Cannabinoid receptor ligands | AbbVie Bahamas Limited (BS) | 2015-07-22 | — | — | EP | disclosed |
| US-8859596-B2 | Compounds as cannabinoid receptor ligands | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| US-8188135-B2 | Compounds as cannabinoid receptor ligands | ABBOTT LABORATORIES (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2428507-A2 | Cannabinoid receptor ligands | Abbott Laboratories (US) | 2012-03-14 | — | — | EP | disclosed |
| EP-2334646-A2 | SUBSTITUTED BENZAMIDES AS CANNABINOID RECEPTOR LIGANDS | Abbott Laboratories (US) | 2011-06-22 | — | — | EP | disclosed |
| WO-2010033543-A2 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069348-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | MEN1 2912/4885KMT2A 2998/4885HTT 4124/4885 |
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | MEN1 4091/4885KMT2A 1635/4885HTT 4164/4885 |
| US-20100069349-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, NPY1R | MEN1 2912/4885KMT2A 2998/4885HTT 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.